Format

Send to

Choose Destination
J Clin Oncol. 2010 Jan 20;28(3):398-404. doi: 10.1200/JCO.2009.25.4920. Epub 2009 Dec 14.

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Author information

1
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. jcortes@mdanderson.org

Abstract

PURPOSE:

Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase.

PATIENTS AND METHODS:

Patients with newly diagnosed CML in early chronic phase were randomly assigned to receive dasatinib 100 mg once daily or 50 mg twice daily as initial therapy.

RESULTS:

Among 50 patients observed for at least 3 months, 49 patients (98%) achieved a complete cytogenetic response (CCyR), and 41 patients (82%) achieved a major molecular response (MMR). Responses occurred rapidly, with 94% of patients achieving CCyR by 6 months. There was no difference in response rate by treatment arm. The projected event-free survival rate at 24 months is 88%, and all patients are alive after a median follow-up time of 24 months. Grade >or= 3 neutropenia and thrombocytopenia occurred in 21% and 10% of patients, respectively. Nonhematologic toxicity was usually grade 1 to 2. There was no significant difference in toxicity between the two arms, and the actual median dose at 12 months was 100 mg (range, 20 to 100 mg).

CONCLUSION:

Dasatinib is an effective agent for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR.

PMID:
20008620
PMCID:
PMC2815702
DOI:
10.1200/JCO.2009.25.4920
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center